PT  - JOURNAL ARTICLE
AU  - Fallon, Braden S.
AU  - Cooke, Elaine M.
AU  - Hesterman, Matthew C.
AU  - Norseth, Jared S.
AU  - Akhundjanov, Sherzod B.
AU  - Weller, Melodie L.
TI  - Significant Disruptions in the International Incidence of Hepatitis Delta Virus
AID  - 10.1101/2021.07.12.21260388
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.12.21260388
4099  - http://medrxiv.org/content/early/2021/07/16/2021.07.12.21260388.short
4100  - http://medrxiv.org/content/early/2021/07/16/2021.07.12.21260388.full
AB  - The international incidence of Hepatitis Delta Virus (HDV) is challenging to accurately estimate due to the limited testing and lack of active surveillance for this rare infectious disease. These limitations prevent the detection of low-level and/or geographically dispersed changes in the incidence of HDV diagnoses. A study was designed to enable international active tracking and analyses of HDV epidemiology by aggregating global HDV diagnoses datasets. Publicly accessible datasets containing yearly incidence for HDV and Hepatitis B Virus (HBV) diagnoses were identified for Argentina, Australia, Austria, Brazil, Bulgaria, Canada, Finland, Germany, Macao, Netherlands, New Zealand, Norway, Sweden, Taiwan, Thailand, United Kingdom, and United States.Aggregated analysis of these HDV and HBV datasets spanning 1999-2020 identified structural breaks in the timeline of HDV incidence in 2002, 2012, and 2017. A significant increase in the international HDV incidence, relative to reported HBV diagnoses, occurred in 2013-2017. Secondary analysis identified four distinct temporal clusters of HDV incidence, including Cluster I (Macao, Taiwan), Cluster II (Argentina, Brazil, Germany, Thailand), Cluster III (Bulgaria, Netherlands, New Zealand, United Kingdom, United States), and Cluster IV (Australia, Austria, Canada, Finland, Norway, Sweden). Additionally, analyses of available demographic data identified a decreasing trend of HDV diagnoses in patients 0-19 years of age and an increasing trend of HDV diagnoses in patients ≥60 years of age. Re-evaluation of the testing paradigm for HDV in HBV-positive patients and an active surveillance status of HDV are warranted to define the etiology of the observed international shifts in HDV incidence.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch reported in this manuscript was supported by The University of Utah, School of Dentistry and National Institute of Dental and Craniofacial Research (NIDCR) of the National Institutes of Health (NIH) under award number R00DE021745.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Analysis of publicly available de-identified data does not constitute human subjects research and does not require IRB review.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll links to data used in study are provided in supplemental table.CDCCenter for Disease ControlNHANESNational Health and Nutritional Examination SurveyBICBayesian Information Criterion